Abstract

Maintenance Rituximab or Observation after Frontline Treatment with Bendamustine-Rituximab (BR) for Follicular Lymphoma: A Real World Analysis Across 13 US Cancer Centers

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Subir Goyal ... Kristie A Blum
Blood | VOL. 134
Subir Goyal, et. al.Subir Goyal ... Kristie A Blum
13 Nov 2019
Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
... Hande H Tuncer
Blood | VOL. 134
, et. al. ... Hande H Tuncer
13 Nov 2019
An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant
Cheolwon Suh ... Giuseppe Rossi
Blood | VOL. 134
Cheolwon Suh, et. al.Cheolwon Suh ... Giuseppe Rossi
13 Nov 2019
Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)
Margaret A Shipp ... Robert A Redd
Blood | VOL. 130
Margaret A Shipp, et. al.Margaret A Shipp ... Robert A Redd
25 Jun 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
Luisa Corrêa De Araujo Koury ... Eduardo M Rego
Blood | VOL. -
Luisa Corrêa De Araujo Koury, et. al.Luisa Corrêa De Araujo Koury ... Eduardo M Rego
28 May 2024
Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of cell cycle.
Carys S Johnson ... Elisa Laurenti
Blood | VOL. -
Carys S Johnson, et. al.Carys S Johnson ... Elisa Laurenti
28 May 2024
CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
Berit J Brinkmann ... Sascha Dietrich
Blood | VOL. -
Berit J Brinkmann, et. al.Berit J Brinkmann ... Sascha Dietrich
28 May 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Matthew J Frigault ... Marcela V Maus
Blood | VOL. -
Matthew J Frigault, et. al.Matthew J Frigault ... Marcela V Maus
23 May 2024
View more papers